PROM1 and esophageal squamous cell carcinoma: Furthermore, inhibition of CD47 by a neutralizing antibody suppressed the self‐renewal function in CD133+ ESCC cells, thereby making the case for CD47 being a promising therapeutic target for ESCC CSCs.